Please see below information about and status of our ongoing clinical trials.

If you are an Eyecare practitioner and would like to refer your patients to us please visit this page. If you are looking to enrol yourself or your children into our trial please click here.

List of clinical trials

TOAST trial

Treatment Outcomes of Atropine

TOAST will be investigating how eye colour can modify the effect of low-dose atropine on the eye. Participants will be aged 18-25 years old and will use 0.01%, 0.02% or 0.05% atropine eye drops at night for two weeks.

Over a 4-week period, we will assess how the low-dose atropine eye drops alter a person’s pupil responses or ability to focus on near objects and determine whether the effects of the eye drops are different between people with lighter coloured eyes (e.g. blue) compared to people with darker eyes (e.g. brown). The results of this study will help to understand what the optimum concentration of atropine is for people with different coloured eyes.

Trial status:

Open for recruitment.

Misight

DOPAVISION trial

The purpose of this clinical trial is to investigate the safety and efficacy of a new non-invasive treatment for myopia control called MyopiaX. The aim of MyopiaX is to slow the progression of myopia in children using a scientifically developed light stimulus and a child-friendly virtual reality game. It is known that light has a positive effect on eye growth and myopia prevention. The goal of our treatment is to provide effective light stimulation aimed at controlling eye elongation and therefore to slow down myopia progression.

Trial status:

Opening for recruitment soon.

OCUMENSION trial

This clinical trial aims to study the safety and efficacy of low-dose atropine (0.01%) eye drops in treating myopia progression in children. Participants aged 3-15 years will be invited to take part in the trial for a 4-year period.

Trial status:

Recruitment is due to start soon, with trial completion expected in 2025.

Misight

MAP trial

MiSight® Analysis of Progression (MAP) Study

MIST is a 3-year study which involves the evaluation of the MiSight®, in comparison to MiSight 2a and 2b which are all intended to slow the progression of juvenile-onset myopia in children. The principle of applying myopic defocus via a dual focus optical design is the basis for the MiSight soft contact lens. You can read more about the MiSight contact lenses by CooperVision here.

Trial status:

Open for recruitment.

MOSAIC trial

Myopia Outcome Study of Atropine in Children

There is no current therapeutic approach to the control and prevention of myopia, which is expected to affect one in three people worldwide by 2020, and represents the only major cause of blindness that is untreatable.

CHAMP and MOSAIC are the first European trials to explore the efficacy and safety of atropine for myopia prevention in a Caucasian population.

Trial status:

Recruitment for the MOSAIC Study is closed with all participants now having been in the study for at least 12 months. The MOSAIC Study is expected to be completed in the late 2023.

Centile charts

CHAMP trial

Children using atropine for reduction of myopia progression

The primary objective of CHAMP is to evaluate the safety & efficacy of 2 concentrations of atropine sulfate ophthalmic solution (0.01% & 0.02%) compared to placebo (vehicle) for the reduction of progression of myopia over a 3-year treatment period.

Trial status:

52 subjects enrolled, recruitment completed. Data collection ongoing (expected completion 2023).

ENIGMA trial

European Nutrition in Glaucoma Management trial

Glaucoma is an age-related neurodegenerative condition that shares associations with cognitive decline, and is one of the major causes of blindness. The focus of the the European Nutrition in Glaucoma Management trial (ENIGMA) is to explore the role of macular pigment (MP), a nutritional biomarker believed to confer neuroprotection along the central nervous system, in glaucoma. This trial will be a first step to develop a novel nutritional therapy that can halt the progression of the disease, and improve the quality of life of people with glaucoma, such as by giving them back their freedom to safely drive at night.

The ENIGMA trial comprises an 18-month double-masked, randomised and placebo-controlled clinical trial to determine the potential benefits of MP supplementation for one of the leading causes of blindness in Ireland and globally.

Loughman, J., Loskutova, E., Butler, J. S., Siah, W. F. & O’Brien, C. Macular Pigment Response to Lutein, Zeaxanthin, and Meso-zeaxanthin Supplementation in Open-Angle Glaucoma: A Randomized Controlled Trial. Ophthalmol. Sci. 1, 100039 (2021). Link to Ophthalmology Science

Trial status:

Recruitment completed. Data collection completed in Sep 2020. Conducting data analysis.